Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Rare solid tumours as indicators of hereditary cancer syndromes

Abstract

Rare tumours are variously defined but usually affect not more than 1 in 100000 people. They can be present at birth, in childhood or later in life. The diagnosis of a rare tumour can sometimes point to an underlying hereditary condition, and one should take into account important considerations that can increase suspicion of a genetic cause of the disease. While some rare neoplasms are highly specific of a hereditary tumour susceptibility syndrome (and can be almost pathognomonic), thus prompting a direct genetic evaluation, most rare neoplasms may appear within the context of multi-tumour susceptibility syndromes, and here they add important weight to the global assessment when considering a genetic referral. Despite their low frequency, novel associations between rare neoplasms and hereditary conditions continue to emerge, although a solid association is often lacking. On the contrary, some infrequent tumours are nearly always non-hereditary (sporadic) in nature. Of note, the definition of rare tumours should be age-adjusted as paediatric tumours are by definition rare when compared with adult tumours in absolute terms. Therefore, in this review, in the paediatric section, we focus on tumours that occur rarely in childhood. This can include cancers that typically occur in adults, but in this case, it appears in a child. Both situations are a strong indication for genetic testing. In this review, we described different scenarios in which rare neoplasms can serve as indications (or not) for an underlying inherited cancer susceptibility.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Scheme with most relevant rare tumour histologies and their associated gene group by topological location of tumours.
The alternative text for this image may have been generated using AI.

Similar content being viewed by others

References

  1. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47:2493–511.

    Article  PubMed  Google Scholar 

  2. Richard S, Campello C, Taillandier L, Parker F, Resche F. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. Fr VHL Study Group J Intern Med. 1998;243:547–53.

    CAS  Google Scholar 

  3. McCluggage WG, Foulkes WD. Rare and unusual tumours associated with characteristic molecular events: the importance of specialist pathology review. Histopathology. 2022;81:310–1.

    Article  PubMed  Google Scholar 

  4. Idos G, Valle L Lynch Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. 1993.

  5. Dominguez-Valentin M, Sampson JR, Moller P, Seppala TT. Analysis in the prospective lynch syndrome database identifies sarcoma as part of the lynch syndrome tumor spectrum. Int J Cancer. 2021;148:512–3.

    Article  CAS  PubMed  Google Scholar 

  6. Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J Clin Oncol. 2013;31:3012–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ferreira I, Wiedemeyer K, Demetter P, Adams DJ, Arends MJ, Brenn T. Update on the pathology, genetics and somatic landscape of sebaceous tumours. Histopathology. 2020;76:640–9.

    Article  PubMed  Google Scholar 

  8. Orta L, Klimstra DS, Qin J, Mecca P, Tang LH, Busam KJ, et al. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient’s age or other clinical characteristics. Am J Surg Pathol. 2009;33:934–44.

    Article  PubMed  Google Scholar 

  9. Colas C, Guerrini-Rousseau L, Suerink M, Gallon R, Kratz CP, Ayuso E, et al. ERN GENTURIS guidelines on constitutional mismatch repair deficiency diagnosis, genetic counselling, surveillance, quality of life, and clinical management. Eur J Hum Genet. 2024;32:1526–41.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Suwala AK, Stichel D, Schrimpf D, Kloor M, Wefers AK, Reinhardt A, et al. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathol. 2021;141:85–100.

    Article  CAS  PubMed  Google Scholar 

  11. Campos FAB, Rouleau E, Torrezan GT, Carraro DM, Casali da Rocha JC, Mantovani HK, et al. Genetic landscape of male breast cancer. Cancers. 2021;13:3535.

  12. Liang M, Zhang Y, Sun C, Rizeq FK, Min M, Shi T, et al. Association between CHEK2*1100delC and breast cancer: a systematic review and meta-analysis. Mol Diagn Ther. 2018;22:397–407.

    Article  CAS  PubMed  Google Scholar 

  13. Schneider K, Zelley K, Nichols KE, Schwartz Levine A, Garber et al. Li-Fraumeni Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. 1993.

  14. Amadou A, Achatz MIW, Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol. 2018;30:23–9.

    Article  CAS  PubMed  Google Scholar 

  15. Kratz CP, Achatz MI, Brugieres L, Frebourg T, Garber JE, Greer MC, et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2017;23:e38–e45.

    Article  CAS  PubMed  Google Scholar 

  16. Lalloo F, Kulkarni A, Chau C, Nielsen M, Sheaff M, Steele J, et al. Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome. Eur J Hum Genet. 2023;31:1261–9.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Eng C, Plitt G Multiple Endocrine Neoplasia Type 2. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. 1993.

  18. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Odintsov I, Papke DJ, George S, Padera RF, Hornick JL, Siegmund SE. Genomic profiling of cardiac angiosarcoma reveals novel targetable KDR variants, recurrent MED12 mutations, and a high burden of germline POT1 alterations. Clin Cancer Res. 2025;31:1091–102.

    Article  CAS  PubMed  Google Scholar 

  20. Hirbe AC, Dehner CA, Dombi E, Eulo V, Gross AM, Sundby T, et al. Contemporary approach to neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Am Soc Clin Oncol Educ Book. 2024;44:e432242.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine. 2023;56:101818.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Zanoletti E, Girasoli L, Borsetto D, Opocher G, Mazzoni A, Martini A. Endolymphatic sac tumour in von Hippel-Lindau disease: management strategies. Acta Otorhinolaryngol Ital. 2017;37:423–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Wu J, Lu J, Wu CL, Lu M. Birt-Hogg-Dube syndrome in an overall view: focus on the clinicopathological prospects in renal tumors. Semin Diagn Pathol. 2024;41:119–24.

    Article  PubMed  Google Scholar 

  24. Degenhardt J, Tolkach Y, Amin MB, Mosiello G, Ertoy Baydar D, Cornec-Le Gall E, et al. The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma. Nephrol Dial Transpl. 2025;40:1428–32.

    Article  CAS  Google Scholar 

  25. Zhang X, Zhao J, Yin X, Liang J, Wang Y, Zheng L, et al. Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets. Nat Commun. 2025;16:4398.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Liu APY, Kelsey MM, Sabbaghian N, Park SH, Deal CL, Esbenshade AJ, et al. Clinical outcomes and complications of pituitary blastoma. J Clin Endocrinol Metab. 2021;106:351–63.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Brenneman M, Field A, Yang J, Williams G, Doros L, Rossi C, et al. Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma / DICER1 syndrome: a unique variant of the two-hit tumor suppression model. F1000Res. 2015;4:214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Witkowski L, Goudie C, Ramos P, Boshari T, Brunet JS, Karnezis AN, et al. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecol Oncol. 2016;141:454–60.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Goudie C, Witkowski L, Vairy S, McCluggage WG, Foulkes WD. Paediatric ovarian tumours and their associated cancer susceptibility syndromes. J Med Genet. 2018;55:1–10.

    Article  PubMed  Google Scholar 

  30. Lohmann DR, Gerick M, Brandt B, Oelschlager U, Lorenz B, Passarge E, et al. Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. Am J Hum Genet. 1997;61:282–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Coorens THH, Treger TD, Al-Saadi R, Moore L, Tran MGB, Mitchell TJ, et al. Embryonal precursors of Wilms tumor. Science. 2019;366:1247–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Witkowski L, Nichols KE, Jongmans M, van Engelen N, de Krijger RR, Herrera-Mullar J, et al. Germline pathogenic SMARCA4 variants in neuroblastoma. J Med Genet. 2023;60:987–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zavoshi S, Lu E, Boutros PC, Zhang L, Harari A, Hatchell KE, et al. Fumarate hydratase variants and their association with paraganglioma/pheochromocytoma. Urology. 2023;176:106–14.

    Article  PubMed  Google Scholar 

  34. Pinto EM, Rodriguez-Galindo C, Lam CG, Ruiz RE, Zambetti GP, Ribeiro RC. Adrenocortical tumors in children with constitutive chromosome 11p15 paternal uniparental disomy: implications for diagnosis and treatment. Front Endocrinol. 2021;12:756523.

    Article  Google Scholar 

  35. Sargen MR, Merrill SL, Chu EY, Nathanson KL. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature. Br J Dermatol. 2016;175:785–9.

    Article  CAS  PubMed  Google Scholar 

  36. Stratakis CA Carney Complex. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. 1993.

  37. Golden T, Siordia JA. Osteochondromyxoma: Review of a rare Carney complex criterion. J Bone Oncol. 2016;5:194–7.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Apellaniz-Ruiz M, Segni M, Kettwig M, Gluer S, Pelletier D, Nguyen VH, et al. Mesenchymal hamartoma of the liver and DICER1 syndrome. N Engl J Med. 2019;380:1834–42.

    Article  CAS  PubMed  Google Scholar 

  39. Mitchell SG, Schultz KAP, Rytting H, Kostelecky N, Hill DA, Dehner LP. DICER1-associated hepatic cystic neoplasm with pleuropulmonary blastoma-like features: a novel clinicopathologic diagnosis. Mod Pathol. 2022;35:676–9.

    Article  CAS  PubMed  Google Scholar 

  40. Pilarski R, Byrne L, Carlo MI, Hanson H, Cebulla C, Abdel-Rahman M BAP1 Tumor Predisposition Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. 1993.

  41. Bruinsma FJ, Dowty JG, Win AK, Goddard LC, Agrawal P, Attina D, et al. Update of penetrance estimates in Birt-Hogg-Dube syndrome. J Med Genet. 2023;60:317–26.

    Article  CAS  PubMed  Google Scholar 

  42. Ouchene L, Udupa M, Mija LA, Moussa S, Chergui M, Watters KA, et al. Assessing the diagnostic metrics of cutaneous leiomyomas in hereditary leiomyomatosis and renal cell cancer syndrome: an observational study. J Am Acad Dermatol. 2025;93:226–8.

    Article  CAS  PubMed  Google Scholar 

  43. Carney JA, Stratakis CA. Epithelioid blue nevus and psammomatous melanotic schwannoma: the unusual pigmented skin tumors of the Carney complex. Semin Diagn Pathol. 1998;15:216–24.

    CAS  PubMed  Google Scholar 

  44. Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJ, Booker SV, et al. Desmoid tumours in familial adenomatous polyposis. Gut. 1994;35:377–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985–99.

    Article  CAS  PubMed  Google Scholar 

  46. Kasper B, Baldini EH, Bonvalot S, Callegaro D, Cardona K, Colombo C, et al. Current management of desmoid tumors: a review. JAMA Oncol. 2024;10:1121–8.

    Article  PubMed  Google Scholar 

  47. Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30:460–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. MacDonald-Jankowski DS. Keratocystic odontogenic tumour: systematic review. Dentomaxillofac Radio. 2011;40:1–23.

    Article  CAS  Google Scholar 

  49. Else T, Rodriguez-Galindo C. 5th International ACC Symposium: hereditary predisposition to childhood ACC and the associated molecular phenotype: 5th international ACC symposium session: not just for kids! Horm Cancer. 2016;7:36–9.

    Article  CAS  PubMed  Google Scholar 

  50. Clay MR, Pinto EM, Fishbein L, Else T, Kiseljak-Vassiliades K. Pathological and genetic stratification for management of adrenocortical carcinoma. J Clin Endocrinol Metab. 2022;107:1159–69.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Weber ML, Schneider DT, Offenmuller S, Kaatsch P, Einsiedel HG, Benesch M, et al. Pediatric colorectal carcinoma is associated with excellent outcome in the context of cancer predisposition syndromes. Pediatr Blood Cancer. 2016;63:611–7.

    Article  PubMed  Google Scholar 

  52. Rebuzzi F, Ulivi P, Tedaldi G Genetic predisposition to colorectal cancer: how many and which genes to test? Int J Mol Sci. 2023;24:2137.

  53. Goudie C, Witkowski L, Cullinan N, Reichman L, Schiller I, Tachdjian M, et al. Performance of the McGill interactive pediatric oncogenetic guidelines for identifying cancer predisposition syndromes. JAMA Oncol. 2021;7:1806–14.

    Article  PubMed  PubMed Central  Google Scholar 

  54. McConechy MK, Farkkila A, Horlings HM, Talhouk A, Unkila-Kallio L, van Meurs HS, et al. Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype. J Natl Cancer Inst. 2016;108:djw134.

  55. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol. 2005;97:519–23.

    Article  PubMed  Google Scholar 

  56. Rabban JT, Karnezis AN, Devine WP. Practical roles for molecular diagnostic testing in ovarian adult granulosa cell tumour, Sertoli-Leydig cell tumour, microcystic stromal tumour and their mimics. Histopathology. 2020;76:11–24.

    Article  PubMed  Google Scholar 

  57. Plevova P, Gerzova H. Genetic causes of rare pediatric ovarian tumors. Klin Onkol. 2019;32:79–91.

    Article  PubMed  Google Scholar 

  58. Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009;266:43–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Dasari A, Wallace K, Halperin DM, Maxwell J, Kunz P, Singh S, et al. Epidemiology of neuroendocrine neoplasms in the US. JAMA Netw Open. 2025;8:e2515798.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Rindi G, Wiedenmann B. Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol. 2020;16:590–607.

    Article  PubMed  Google Scholar 

  61. Metz DC, Cadiot G, Poitras P, Ito T, Jensen RT. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol. 2017;4:167–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65–71.

    Article  CAS  PubMed  Google Scholar 

  63. Smith NJ, Mukherjee D, Wang Y, Brazauskas R, Nelson AA, Cortina CS. Epidemiology and outcomes of primary pediatric lung malignancies: Updates from the SEER database. Am J Surg. 2021;222:861–6.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Thibodeau ML, O’Neill K, Dixon K, Reisle C, Mungall KL, Krzywinski M, et al. Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing. Genet Med. 2020;22:1892–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Horton C, Hoang L, Zimmermann H, Young C, Grzybowski J, Durda K, et al. Diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary cancer testing. JAMA Oncol. 2024;10:212–9.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385:2036–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382:1430–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Guerrini-Rousseau L, Varlet P, Colas C, Andreiuolo F, Bourdeaut F, Dahan K, et al. Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium. Neurooncol Adv. 2019;1:vdz033.

    PubMed  PubMed Central  Google Scholar 

  69. Gounder M, Schoffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21:1423–32.

    Article  CAS  PubMed  Google Scholar 

  70. Boyd N, Dancey JE, Gilks CB, Huntsman DG. Rare cancers: a sea of opportunity. Lancet Oncol. 2016;17:e52–e61.

    Article  PubMed  Google Scholar 

  71. Pappo AS, Furman WL, Schultz KA, Ferrari A, Helman L, Krailo MD. Rare tumors in children: progress through collaboration. J Clin Oncol. 2015;33:3047–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

BR is a Miguel Servet Fellow (CP21/00038) from the Instituto de Salud Carlos III. This work has been supported by Consolidator Grant (CNS2023-144251) to BR, funded by MCIN/AEI and by “European Union NextGenerationEU/PRTR”.

Author information

Authors and Affiliations

Authors

Contributions

The authors declare no competing interests.

Corresponding author

Correspondence to Barbara Rivera.

Ethics declarations

Competing interests

Authors has nothing to disclose

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rivera, B., Torrezan, G.T., Roca, C. et al. Rare solid tumours as indicators of hereditary cancer syndromes. Eur J Hum Genet (2026). https://doi.org/10.1038/s41431-026-02091-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41431-026-02091-0

Search

Quick links